Premium
CVP—Remission—maintenance in stage I or II non‐Hodgkin's lymphomas Preliminary results of a randomized study
Author(s) -
Landberg Torsten G.,
Håkansson Leif G.,
Möller Torgil R.,
Mattsson Willy K. I.,
Landys Karol E.,
Johansson Bo G.,
Killander Dick C. F.,
Molin Bjö Rn F.,
Westling Per F.,
Lenner Per H.,
Dahl Olov G.
Publication year - 1979
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197909)44:3<831::aid-cncr2820440307>3.0.co;2-s
Subject(s) - medicine , vincristine , radiation therapy , cyclophosphamide , chemotherapy , lomustine , randomized controlled trial , prednisolone , stage (stratigraphy) , surgery , lymphoma , paleontology , biology
The effect of adjuvant combination chemotherapy when given to nonlaparotomized patients in remission after radiotherapy in stage I or II non‐Hodgkin's lymphoma was studied in a prospective randomized multicenter study. Locally extended field radiotherapy was given to a target absorbed dose of 40 Gy in 20 fractions. Fifty‐five patients who were in complete remission 6 weeks after conclusion of radiotherapy were randomized to either no further therapy or to 9 cycles of CVP (cyclophosphamide +vincristine +prednisolone). The relapse‐free survival at 30 months was 41% for patients without and 86% for patients with adjuvant chemotherapy (p = 0.02). The survival was the same for both treatment arms, being 90% at 30 months. Fifteen patients have relapsed, 14 of them with extensions and 1 with a recurrence within the radiation target volume. Analysis of subgroups showed that adjuvant chemotherapy in the present series significantly prolonged the relapse‐free survival in diffuse histiocytic lymphoma.